Paolo Tarantino: How long should adjuvant T-DM1 be given for stage I HER2+ eBC?
Paolo Tarantino shared on X:
“For how long should adjuvant T-DM1 be given for stage I HER2+ eBC?
ATEMPT used 1 year of T-DM1, which should be the goal. Yet none of the 37 pts that discontinued early (<6 mo) recurred.
ATEMPT 2.0 ongoing to validate a shorter course of T-DM1 (6 cycles).”
Source: Paolo Tarantino/X
Paolo Tarantino, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.